Member Info for BuenaVista

And what do Tempus want to get from the collaboration? Well payment in cash and/or kind. As a 'collaboration', Avacta could make their patient data from clinical trials available to Tempus, as JT wrote in another thread. Would that be enough, being end-loaded? Given that "Tempus's analytical support and computational biology experts will collaborate in the data analysis with the Avacta team", I'd be surprised if there wasn't some upfront payment as well.

Do CAFs evolve? It is the cancer cells that are out of control and evolve. FAP is involved in tissue remodelling - growth, cancer and scarring. I don't know whether its role in remodelling is vital, whether there are other biochemical pathways.

I think Avacta may be hoping to get two things out of this collaboration. Firstly to identify cancer types with active FAP that would be susceptible to treatment with pre|CISION drugs and secondly, given the heterogeneity between patients with the same cancer type, to identify those patients with those cancers who are likely to benefit from pre|CISION treatment in clinical trials.

RNS by 3pm

If there are no FAP-expressing CAFs left, then there is no cancer left, so yes, it does render the AVA medicines inert. That's putting it simply. It may be a bit more complex than that but basically, FAP no longer being overexpressed means the cancer has gone.

Key Benefits of These Collaborations:

Precision Medicine: Pharmaceutical companies gain access to Tempus’ massive database of de-identified clinical and molecular data, which helps them tailor cancer therapies to individual patients.

Faster Drug Development: By leveraging AI and machine learning, Tempus aids pharmaceutical companies in expediting the development of targeted therapies and optimizing clinical trial designs.

Improved Clinical Trials: Tempus helps pharmaceutical partners identify suitable patients for trials through biomarker analysis and real-world data, thus improving trial efficiency and outcomes.

These collaborations underscore Tempus' role as a pivotal partner in the pharmaceutical industry, using AI and data-driven insights to revolutionize precision medicine.

Prompt: What are the details of Tempus AI's collaborations with pharmaceutical companies?

ChatGPT4 response: Tempus AI has formed several notable collaborations with pharmaceutical companies to advance drug development, clinical trials, and precision medicine. These partnerships leverage Tempus' vast clinical and molecular data, as well as its artificial intelligence and machine learning capabilities. Here are the key details of some of Tempus AI's collaborations:

1. Partnership with Pfizer:

Focus: Tempus partnered with Pfizer in 2020 to use its AI-driven platform to identify actionable insights from clinical and molecular data for Pfizer's oncology programs.

Goals: The partnership aims to enhance drug discovery, optimize clinical trials, and identify potential biomarkers for cancer treatments.

Real-World Data: Tempus provides real-world evidence by linking clinical data to genomic profiles, aiding in the development of personalized cancer therapies.

2. Collaboration with Eli Lilly:

Focus: In 2019, Tempus entered into a partnership with Eli Lilly to use Tempus’ genomic data platform for cancer research and precision medicine initiatives.

Data-Driven Approach: The collaboration allows Eli Lilly to leverage Tempus’ vast genomic and clinical data to accelerate its oncology drug development. Lilly uses Tempus’ resources to refine its clinical trial processes by improving patient selection and understanding the underlying biology of tumors.

3. Partnership with Novartis:

Objective: Tempus collaborated with Novartis to drive precision medicine efforts in oncology.

Focus on Clinical Trials: The goal of this collaboration is to speed up recruitment for clinical trials by using Tempus' real-world data and analytics platform to identify eligible patients more effectively. The partnership also aims to improve trial design by focusing on genomic insights.

4. Bristol-Myers Squibb (BMS):

Objective: In 2018, Tempus teamed up with Bristol-Myers Squibb to leverage Tempus’ AI platform for oncology trials.

Clinical Trial Optimization: This collaboration is geared toward using Tempus’ data and AI tools to optimize BMS's clinical trials, especially in identifying the right patients for immuno-oncology therapies.

5. Collaboration with Amgen:

Focus: Tempus worked with Amgen to use its machine learning models and molecular data to improve the efficiency of Amgen’s oncology research, focusing on biomarker discovery and better therapeutic targeting.

Data Integration: Amgen utilizes Tempus’ data analytics to guide patient enrollment and drug development decisions based on genomic profiles.

6. AstraZeneca Partnership:

Objective: AstraZeneca collaborates with Tempus to harness real-world data and machine learning in identifying novel therapeutic approaches for cancer. AstraZeneca uses Tempus' AI-powered data platform to enhance the precision and personalization of oncology treatments.

I wish solicitors would use this pay to use our services model.

Where did it say that?

For Tempus AI's collaborations with other companies and the sort of thing they involve, see https://www.tempus.com/news/pr/

If there's a Tempus press release later today, we may get more detail about the Avacta collaboration.

RNSes have been between noon and 3pm except for one just before 11am.

Https://en.m.wikipedia.org/wiki/Bone_sarcoma

A bone sarcoma is a primary malignant bone tumour, a type of sarcoma that starts in the bones.[1] This is in contrast to most bone cancers that are secondary having developed as a metastasis from another cancer. Bone sarcomas are rare, and mostly affect the legs. The other type of sarcoma is a soft-tissue sarcoma.

😁

Yes, it all depends on the quality/specificity of the question asked, like asking about exatecan patents.

Me: Will Avacta save Cinderella?

ChatGPT4: It sounds like you’re referring to Avacta's work in the biotech field, possibly in relation to cancer treatments or diagnostics, and “Cinderella” could be a metaphor for a groundbreaking innovation. In the context of biotech, breakthroughs often feel like fairy tales, where a promising technology can transform patient outcomes. If Avacta has a promising approach, it could indeed be a game changer! Do you have a specific context in mind?

Me: Will Avacta be able to wake Sleeping Beauty?

ChatGPT4: If "Sleeping Beauty" refers to a promising but underappreciated treatment or technology in the biotech space, then yes, companies like Avacta are working to "wake" those potential breakthroughs through their research and innovations. In biotech, many ideas or therapies can take time to develop before they can truly shine. If Avacta continues to advance its research, it could very well lead to significant advancements in treatments. What specific aspect of Avacta’s work are you curious about?

At the bottom of the ChatGPT page there is a little note that says "ChatGPT can make mistakes. Check important info." So beware of dumb AI.

So AI?

Me: Please provide the sources YOU USED

ChatGPT4: I don’t have direct access to external sources or databases, so I can’t pull up specific articles or press releases. However, I based my information on common knowledge about industry collaborations and the types of sources typically used to track them.

To find accurate and specific information about the partnership, I recommend checking:

Avacta's Official Website: Look for their news or investor relations section.

Novartis's Official Website: They also have a dedicated section for press releases and news.

Industry News Sites: Searching on platforms like BioSpace, FierceBiotech, or Endpoints News can yield relevant articles.

Financial Reports and Market Analysis: Websites that provide industry analysis may have reports on the collaboration.

If you’re looking for specific articles or documents, you may want to search directly using keywords like “Avacta Novartis partnership” in those sources.

Me: please provide specific sources

ChatGPT4: Here are some specific sources where you can find detailed information about the partnership between Avacta and Novartis:

Avacta Group Press Releases:

Check the official Avacta website under their "News" or "Investors" section for announcements regarding their partnership with Novartis. Avacta News

Novartis Press Releases:

Visit the Novartis website and navigate to their press releases for details about collaborations. Novartis News

Market Research Reports:

Reports from firms like Evaluate Pharma or GlobalData often cover industry partnerships. You might need a subscription to access some reports.

Financial News Articles:

Websites like FierceBiotech, Endpoints News, or BioSpace frequently report on biotech partnerships. You can search for articles specifically mentioning Avacta and Novartis:

FierceBiotech

Endpoints News

BioSpace

Scientific Journals:

Look for articles published in journals like Nature Reviews Drug Discovery or Journal of Pharmaceutical Sciences for insights into the technologies involved.

Using these sources should help you find comprehensive and reliable information on the partnership between Avacta and Novartis.

Me: please provide sources for that

ChatGPT4: For the most accurate and detailed information about the partnership between Avacta and Novartis, you can refer to:

Official Press Releases: Both companies often issue press releases that outline the details of their collaborations. You can find these on their respective websites in the news or investor relations sections.

Financial News Websites: Platforms like Bloomberg, Reuters, or BioSpace frequently report on pharmaceutical partnerships and may have articles discussing this specific collaboration.

Scientific Journals: Occasionally, collaborations will be discussed in journals that publish research related to the therapeutic areas they are focusing on.

Regulatory Filings: If either company is publicly traded, their filings with regulatory bodies like the SEC (in the U.S.) can provide detailed information about significant partnerships.

Industry Reports: Market research firms may publish analyses that include discussions of partnerships in the biotech and pharmaceutical industries.

You can search these sources for the most current and comprehensive information regarding the Avacta and Novartis partnership.

It was very tedious, but this is how it went...

Me: What's the partnership relationship between avacta and novartis?

Chat GPT4: Avacta and Novartis have entered into a partnership focused on developing innovative therapeutics, particularly in the field of cancer treatment. The collaboration leverages Avacta's Affimer technology, which is designed to create highly specific and effective drugs.

This partnership aims to combine Avacta's novel drug modalities with Novartis's extensive resources and expertise in drug development and commercialization. Together, they seek to enhance the efficacy of treatments and potentially accelerate the path to market for new therapies.

If you're looking for specific details about the partnership, such as financial terms or project timelines, I can provide general insights, but specific numbers might not be publicly available.